SCHEMBL6289282

SCHEMBL6289282

Cn1cc(Cc2ccccc2)c(=O)c2sc(C#CCc3ccccc3)nc21

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.34
PLA2G7 Q13093 1/20 0.34
BRD4 O60885 1/20 0.33
DHFR P00374 1/20 0.33
ADORA2A P29274 1/20 0.33
ADORA1 P30542 1/20 0.33
P2RX7 Q99572 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.32
EGFR P00533 2/20 0.32
PDGFRB P09619 2/20 0.32
KDR P35968 2/20 0.32
LMNA P02545 3/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
PDE3B Q13370 1/20 0.32
PDE3A Q14432 1/20 0.32
TSHR P16473 1/20 0.31
TTR P02766 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6289356 0.78 TSHR (0.38) RXFP1PLA2G7BRD4DHFRL3MBTL1
SCHEMBL6289021 0.77 MMP13 (0.35) PLA2G7EGFRPDGFRBKDRSMN1; SMN2
SCHEMBL6292111 0.72 MMP13 (0.36) RXFP1PLA2G7P2RX7SMN1; SMN2TSHR
SCHEMBL6288743 0.69 MMP13 (0.37) BRD4PDE3BPDE3A
SCHEMBL6289351 0.66 MMP13 (0.35) PLA2G7BRD4SMN1; SMN2TSHR
SCHEMBL6289024 0.65 PLA2G7 (0.33) PLA2G7BRD4PDE3BPDE3A
SCHEMBL11494803 0.63 PDE3B (0.43) BRD4DHFRADORA2AADORA1PDE3B
SCHEMBL6292839 0.63 MMP13 (0.38) RXFP1PLA2G7BRD4LMNASMN1; SMN2
SCHEMBL6292732 0.63 GPR55 (0.36) RXFP1PLA2G7BRD4L3MBTL1LMNA
SCHEMBL6292115 0.63 MMP13 (0.36) PLA2G7P2RX7PDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040034054-A1 Fused bicyclic metalloproteinase inhibitors LINCOLN FOODSERVICE PRODUCTS INC. 2004-02-19 US claimed
WO-2004014375-A2 FUSED BICYCLIC METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO claimed
US-6949651-B2 Fused bicyclic metalloproteinase inhibitors WARNER-LAMBERT COMPANY (US) 2005-09-27 US disclosed
US-20040034054-A1 Fused bicyclic metalloproteinase inhibitors LINCOLN FOODSERVICE PRODUCTS INC. 2004-02-19 US disclosed
WO-2004014375-A2 FUSED BICYCLIC METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034054-A1 Fused bicyclic metalloproteinase inhibitors MMP9, MMP1, MMP2 RXFP1 528/4885PLA2G7 189/4885BRD4 336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.